Roivant Sciences (ROIV) Operating Leases (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Operating Leases came in at $107.4 million in Q1 2026, up 18.94% YoY from $90.3 million in Q1 2025, and up 9.07% on a QoQ basis from $98.5 million in Q4 2025.
Roivant Sciences (ROIV) Operating Leases (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Operating Leases data on file, last reported at $107.4 million in Q1 2026.
- Quarterly Operating Leases rose 18.94% year-over-year to $107.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.4 million (up 18.94% YoY) and the FY2026 annual result came in at $107.4 million, up 18.94% from the prior year.
- Operating Leases rose to $107.4 million in Q1 2026, from $98.5 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $107.4 million in Q1 2026 to a low of $45.0 million in Q1 2024.
- A 5-year average of $67.0 million and a median of $54.9 million in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases retreated 17.06% — and 2025, when it jumped 100.64%.
- Tracing ROIV's Operating Leases over 5 years: stood at $54.9 million in 2022, then declined by 14.32% to $47.1 million in 2023, then surged by 92.27% to $90.5 million in 2024, then grew by 8.87% to $98.5 million in 2025, then gained by 9.07% to $107.4 million in 2026.
- The last three Operating Leases figures came in at $107.4 million (Q1 2026), $98.5 million (Q4 2025), and $89.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.77 Mn |
| Mar 31, 2026 | 107.44 Mn |
| Dec 31, 2025 | 98.50 Mn |
| Sep 30, 2025 | 89.84 Mn |
| Jun 30, 2025 | 90.29 Mn |
| Mar 31, 2025 | 90.33 Mn |
| Dec 31, 2024 | 90.48 Mn |
| Sep 30, 2024 | 49.10 Mn |
| Jun 30, 2024 | 45.85 Mn |
| Mar 31, 2024 | 45.02 Mn |
| Dec 31, 2023 | 47.06 Mn |
| Sep 30, 2023 | 48.63 Mn |
| Jun 30, 2023 | 51.81 Mn |
| Mar 31, 2023 | 53.48 Mn |
| Dec 31, 2022 | 54.93 Mn |
| Sep 30, 2022 | 54.09 Mn |
| Jun 30, 2022 | 60.40 Mn |
| Mar 31, 2022 | 62.47 Mn |
| Dec 31, 2021 | 62.09 Mn |
| Sep 30, 2021 | 65.22 Mn |